ClinicalTrials.gg
TerminatedNCT01388933Updated Jun 11, 2015

A Safety and Efficacy Study of Daikenchuto (TU-100) to Treat Crohn's Disease

A Phase 2 interventional study of TU-100 and Matching Placebo in Crohn's Disease, sponsored by Tsumura USA. Terminated at 27 sites in United States. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2015-06-11.

Sponsored by Tsumura USA · Phase 2, Interventional, and Treatment

Why this study was terminated
Study stopped due to low enrollment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
79
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 660 studies in Crohn Disease with a site in United States — 122 open to participants now, 163 under way, 35 of them phase 3. Crohn Disease · United States.

Enrollment
229th of 528
79 · median 60
Started
2011
with 32 others
Phase 2
141 of 660
23 open now
Registered
185th of 660
by date

Among the 660 studies in Crohn Disease with a site in United States, this one is the 229th largest by enrollment of the 528 interventional ones that give a count, is one of 33 that started in 2011, is one of 141 in phase 2, and was the 185th registered.

Crohn Disease

1,993 studies on the registry are indexed under Crohn Disease; 478 are open to participants now.

Browse Crohn Disease studies →

Open to participants now

122 of the 660 studies in Crohn Disease with a site in United States are open now. Recruiting first, the newest first:

117 more — sign in →

All 122 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 353 Crohn Disease studies recruiting now, 154 (44%) set no upper age limit and 144 (41%) stop at 75 or younger; 95 take children under 18; 56 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 660 studies in Crohn Disease with a site in United States, or all of them as a file.
02

Study summary

The purpose of this study is to determine whether Daikenchuto(TU-100)is effective in the treatment of Crohn's disease.

Read the detailed description

Crohn's disease, a chronic condition resulting in inflammation of the gastrointestinal tract (GI), causes a person to experience persistent symptoms of inflammatory bowel disease, including abdominal pain, nausea, vomiting, rectal bleeding, diarrhea, and constipation, with infrequent bowel movements that are at times accompanied by a sensation of incomplete emptying after having a bowel movement. Tsumura's TU-100 is a modern herbal product that has been approved as a prescription drug in Japan. Several lines of evidence indicate that TU-100 attenuates intestinal inflammation in Crohn's disease by increasing intestinal blood flow and stimulating a protective lining of intestinal mucus which produces an anti-inflammatory effect. TU-100 may attenuate pathological changes in the intestine and reduce symptoms in patients with Crohn's disease.

03

Conditions studied

  • Crohn's Disease

Keywords

  • Crohn's Disease
  • natural
  • herbal
  • Kampo
  • inflammatory bowel disease
  • Adult ages 18 to 75
  • Male and female subjects
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • provide written
  • ability to orally ingest study medication
  • male or female between 18 to 75 inclusive
  • diagnosed with Crohn's disease for at least 3 months
  • CDAI score of 220-300 at screening
  • sexually active participants of must agree to
  • no conditions which the doctor would feel exclusionary
  • stable medication (including probiotics)

Exclusion criteria

Exclusion Criteria:

  • history of any bowel condition that may interfere with the evaluation of the study drug
  • positive stool cultures
  • currently pregnant or lactating
  • receiving total parenteral nutrition
  • history of alcohol or drug abuse within one year
  • history of within 5 years
  • current use of anticholinergic agents, antidepressants during the study, warfarin, prokinetics, antipsychotic agents or narcotic analgesics
  • treatment with Anti-TNF agents 12 weeks before screening
  • treatment with four weeks prior to screening
  • treatment with cyclosporine or tacrolimus eight weeks prior to screening
  • presence of a poorly controlled medical condition
  • history of allergic reaction to ginseng, ginger or sichuan pepper
  • any use of supplemental ginger, ginseng and Sichuan powder 2 weeks prior to and through course of the trial
  • current use of any of the following herbal medications: Boswellia, Cat's claw (Uncaria tomentosa), Cayenne pepper, Echinacea, Horsetail (Equisetum), Hops, Lady's mantle (Alchemilla), Marshmallow root (Althaea), Slippery elm (Ulmus rubra) Turmeric and White Willow (Salix alba)
  • history of celiac disease
  • current diagnosis of lactose intolerance
  • history of any other medication within 30 days of enrolling in study
  • unsuitability as determined by the study doctor
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
79 participants (actual)

Study arms

  • Experimental
    TU-100

    15g TU-100 (oral, daily) for 8 consecutive weeks (administered as 5g three times daily)

    Drug: TU-100

  • Placebo comparator
    Matching placebo

    Matching placebo given 5g three times daily orally for 8 consecutive weeks

    Drug: Matching Placebo

Interventions

  • DrugTU-100

    15g daily, orally as 5g three times daily for 8 consecutive weeks

    Also known as: Daikenchuto

  • DrugMatching Placebo

    15g as 5g three times daily, orally for 8 consecutive weeks

    Also known as: Placebo

06

What researchers measure

Primary outcomes

  1. Clinical response as measured by a reduction in the CDAI total score

    Time frame: over eight weeks

Secondary outcomes

  1. CDAI reduction by number of points and difference from baseline

    Time frame: over eight weeks

  2. proportion of subjects showing a clinical remission by measure of CDAI score

    Time frame: over eight weeks

  3. The change in total CDAI score

    Time frame: every four weeks over eight weeks

  4. The change in IBDQ total score and category sub-scores

    Time frame: every four weeks over eight weeks

  5. The change in CRP level

    Time frame: every four weeks over eight weeks

  6. The change in fecal calprotectin levels

    Time frame: over eight weeks

07

Study locations

27 sites
  • Preferred Research Partners Inc
    Little Rock, Arkansas 72211, United States
  • TRIMED Clinical Trials
    Corona, California 92880, United States
  • Digestive Care Associates, LLC
    San Carlos, California 94070, United States
  • University of California at San Francisco
    San Francisco, California 94115, United States
  • Rocky Mountain Gastroenterology Associates
    Lakewood, Colorado 80215, United States
  • Clinical Research of West Florida, Inc
    Clearwater, Florida 22765, United States
  • Gastroenterology Group of Naples
    Naples, Florida 34102, United States
  • Shafran Gastroenterology Center
    Winter Park, Florida 32789, United States
  • Atlanta Gastroenterology Associates, LLC
    Atlanta, Georgia 30542-5020, United States
  • Gastroenterology Associates of Central Georgia
    Macon, Georgia 31210, United States
  • University of Chicago Hospital Medical Center
    Chicago, Illinois 60637, United States
  • University of Louisville School of Medicine
    Louisville, Kentucky 40202, United States
  • Metropolitan Gastroenterology Group. PC
    Chevy Chase, Maryland 20815, United States
  • Endoscopic Microsurgery Associates PA
    Towson, Maryland 21204, United States
  • MedRACS
    Quincy, Massachusetts 02169, United States
  • Clinical Research Institute of Michigan
    Chesterfield, Michigan 48047, United States
  • Center for Digestive Health
    Troy, Michigan 48098, United States
  • Digestive Health Center
    Ocean Springs, Mississippi 39564, United States
  • St. Louis Center for Clinical Research
    St. Louis, Missouri 63128, United States
  • Long Island Clinical Research Associates, LLP
    Great Neck, New York 11021, United States
  • NY Scientific CORP
    Hollis, New York 11423, United States
  • PMG Research of Salisbury
    Salisbury, North Carolina 28144, United States
  • PMG Research of Winston-Salem, LLC
    Winston-Salem, North Carolina 27103, United States
  • Ohio Gastroenterology and Liver
    Cincinnati, Ohio 45014, United States
  • Consultants for Clinical Research
    Cincinnati, Ohio 45219, United States
  • Advanced Research Institute
    Ogden, Utah 84405, United States
  • University of Washington Medical Center
    Seattle, Washington 98195, United States
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Sep 2011, a primary completion of Sep 2013 and a completion of Sep 2013. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 5, 2011
First posted
Jul 7, 2011
Start
Sep 2011
Primary completionActual
Sep 2013
CompletionActual
Sep 2013
Results delay requested
May 18, 2015
Last update
Jun 11, 2015
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 11, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01388933
Lead sponsor
Tsumura USA
Collaborators
Syneos Health
Responsible party
Sponsor
First posted
Jul 7, 2011
Start date
Sep 2011
Primary completion
Sep 2013
Completion
Sep 2013
Last update
Jun 11, 2015

Study contacts

Shunji Mochida, Ph.D.
study director · Tsumura USA

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in May 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tu-100

Start the discussion